Impact of systemic inflammation and sarcopenia on prognosis of metastatic colorectal cancer.

Authors

David da Silva Dias

David da Silva Dias

Centro Hospitalar Universitário do Algarve, Faro, Portugal

David da Silva Dias , Mafalda Machado , Beatriz Gosalbez , Paula Ravasco

Organizations

Centro Hospitalar Universitário do Algarve, Faro, Portugal, Centre for Interdisciplinar Research in Health, Universidade Católica Portuguesa, Lisbon, Portugal

Research Funding

No funding received
None

Background: Systemic inflammation, evaluated with neutrophil-to-lymphocyte ratio (NLR), and sarcopenia, assessed with skeletal muscle index (SMI), appear to predict mortality in many cancers, although the optimal cut-offs are still a matter of debate. The goal of this study is to evaluate the cut-offs of NLR and SMI and their prognostic value on metastatic colorectal cancer (mCRC) under first line treatment. Methods: Retrospective cohort analysis of patients with mCRC under first-line treatment in two hospital units, between January 2015 and December 2018. Muscle mass area (MMA) was detected on computed tomography, on L3 segment, with ImageJ software. SMI was determined as MMA/height2. Statistical analysis was performed with IBM SPSS v25 software.Results: 178 patients were analysed, with mean age of 62 (±11) years old. 65% were male and 62.9% had ECOG PS 0. Two thirds of patients presented metastasis in a single organ, mainly in liver. The cut-off values were established based on ROC analysis. Systemic inflammation was defined as NLR > 2.80 and sarcopenia was defined by SMI < 49.12 cm2/m2 for men and <35.85 cm2/m2 for women. 52% of patients presented sarcopenia. In a multivariate analysis using a Cox regression model, an association was observed between overall survival and ECOG PS (p=0.014; HR 5.46, CI 95% [1.42-21.10]), systemic inflammation (p=0,038; HR 2.20, CI 95% [1,05-4.62]) and sarcopenia (p=0.01; HR 4.73, CI 95% [1.85-12.09]). Conclusions: In this study, sarcopenia and systemic inflammation showed independent prognostic value on patients with mCRC. Future prospective studies are necessary to establish a definitive cut-off value for application in clinical practice.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Colorectal Cancer

Track

Colorectal Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr 38)

DOI

10.1200/JCO.2021.39.3_suppl.38

Abstract #

38

Poster Bd #

Online Only

Abstract Disclosures

Similar Abstracts

Abstract

2020 ASCO Virtual Scientific Program

The role of Systemic Inflammation Score (SIS) in BRAF(V600) mutant metastatic colorectal cancer (mCRC).

First Author: Nieves Martinez Lago

Abstract

2023 ASCO Gastrointestinal Cancers Symposium

Neutrophil-to-lymphocyte ratio and clinical outcomes in liver resection for metastatic colorectal cancer.

First Author: Sarah Reddy